Filtered By:
Condition: Hypertension
Nutrition: Calcium
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 337 results found since Jan 2013.
Increased ionized calcium-magnesium-ratio in elderly hypertensives - relationship to artheriosclerosis
CONCLUSIONS: As described earlier, a magnesium deficiency can be involved in the pathogenesis of hypertension and in elderly.The increased calcium-magnesium-ratio is also a pathogenetic factor for artheriosclerosis often found in elderly hypertensives with vascular damage, e.g. stroke, renal insufficiency or heart disease.PMID:36026911 | DOI:10.1097/01.hjh.0000836640.98666.86
Source: Atherosclerosis - August 26, 2022 Category: Cardiology Authors: Kisters Kisters Klaus Kisters Lukas Gremmler Bernhard Sprenger Jutta Gr öber Uwe Source Type: research
Molecular explanation of Wnt/ βcatenin antagonist pyrvinium mediated calcium equilibrium changes in aging cardiovascular disorders
Mol Biol Rep. 2022 Sep 15. doi: 10.1007/s11033-022-07863-7. Online ahead of print.ABSTRACTThe symptoms of ageing are somewhat different and can lead to the altered role of the cardiovascular system at the levels of genetic, biochemical, tissue, organ, and systems. Ageing is an autonomous cardiovascular risk factor. In the ageing rat heart, oxidative and inflammatory stress, immune cell infiltration, increasing myeloperoxidase function, elevated caspase-3 activity, and protein fibronectins were detected and associated with ageing and cardiovascular disease. The intracellular Ca2 + homeostasis disturbed in an older heart dra...
Source: Molecular Biology Reports - September 15, 2022 Category: Molecular Biology Authors: Khalid Saad Alharbi Yogendra Singh Obaid Afzal Abdulmalik Saleh Alfawaz Altamimi Imran Kazmi Fahad A Al-Abbasi Sami I Alzarea Dinesh Kumar Chellappan Sachin Kumar Singh Kamal Dua Gaurav Gupta Source Type: research
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
Predictive values of coronary artery calcium and arterial stiffness for long-term cardiovascular events in patients with stable coronary artery disease
CONCLUSIONS: A CAC score ≥100 or a CAVI ≥ 9.0 predicts the long-term occurrence of MACEs in both asymptomatic and symptomatic patients with stable CAD. These two noninvasive tests can be used as screening tools to guide treatment for the prevention of future CV events.PMID:36448219 | DOI:10.1002/clc.23955
Source: Atherosclerosis - November 30, 2022 Category: Cardiology Authors: Thosaphol Limpijankit Sutipong Jongjirasiri Krissada Meemook Nattawut Unwanatham Ammarin Thakkinstian Jiraporn Laothamatas Source Type: research
Mechanism of Hypoxia-Mediated Smooth Muscle Cell Proliferation Leading to Vascular Remodeling
Biomed Res Int. 2022 Dec 24;2022:3959845. doi: 10.1155/2022/3959845. eCollection 2022.ABSTRACTVascular remodeling refers to changes in the size, contraction, distribution, and flow rate of blood vessels and even changes in vascular function. Vascular remodeling can cause cardiovascular and cerebrovascular diseases. It can also lead to other systemic diseases, such as pulmonary hypertension, pulmonary atherosclerosis, chronic obstructive pulmonary disease, stroke, and ascites of broilers. Hypoxia is one of the main causes of vascular remodeling. Prolonged hypoxia or intermittent hypoxia can lead to loss of lung ventilation,...
Source: Cell Research - January 3, 2023 Category: Cytology Authors: Xiaojuan Huang Elif Ece Akg ün Khalid Mehmood Hui Zhang Zhaoxin Tang Ying Li Source Type: research
